Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus
Authors' conclusion
Weight loss following treatment with liraglutide was associated with reduced circulating levels of sCD163 when compared to the same extent of weight loss after lifestyle changes. This might contribute to reduced cardiometabolic risk in individuals receiving treatment with liraglutide.
Study context
- Population
- Obese individuals with prediabetes or T2D diagnosed within the last 12 months
- Participants
- 20 / 20 / 13
- Comparison
- Liraglutide vs lifestyle intervention after comparable weight loss
- Lifestylen = 20reference
- Liraglutiden = 20
- Healthyn = 13
- Outcome
- Plasma sCD163
- Follow-up
- After weight loss
Main finding
As reported in the abstract
- sCD163 decreased significantly in the liraglutide group vs lifestyle
- Liraglutide vs Lifestyle: between-group difference p = 0.023
Further findings
Myeloperoxidase (MPO) and LIGHT · after weight loss
- MPO and LIGHT decreased significantly only with liraglutide (between-group difference not significant)
Baseline markers, cases vs controls
- sCD163 and LIGHT higher in cases than controls
- sCD14, neutrophil gelatinase-associated lipocalin (NGAL), sTIM-3 and sCD25 did not differ between patients and controls
Correlations
- MPO and in particular sCD163 correlated with markers of metabolic dysfunction and inflammation
sCD163 during OGTT · after weight loss
- Only sCD163 showed a trend for decreased levels during OGTT, in the whole cohort and liraglutide vs lifestyle
Original publication
Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus. Cardiovasc Diabetol. Published 29 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →